Literature DB >> 27214710

Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors.

D D Ribeiro1,2, W M Lijfering1,3, F R Rosendaal1,3,4, S C Cannegieter1,3.   

Abstract

UNLABELLED: Essentials Obesity, factor V Leiden (FVL) and blood group non-O are common. We studied the combined effect of these factors on the risk of venous thrombosis (VT). The combination of obesity, non-O blood group and FVL increased VT risk up to ten-fold. Identifying high VT may be beneficial in thrombosis prevention.
SUMMARY: Background Overweight/obesity has a substantial effect on the occurrence of venous thrombosis (VT). Blood group non-O has a high prevalence in Western populations, and the factor V Leiden mutation could be present in 5% of Caucasians. These frequent prothrombotic risk factors will have a considerable impact on the incidence of VT, especially when combined. Objectives We investigated whether FV Leiden with blood group non-O modifies VT risk in individuals with different body mass index (BMI) strata in a case-control study (n = 11253). Results We observed a progressively increasing risk of VT with higher BMI, with an odds ratio of 1.9 (95% confidence interval [CI] 1.6-2.3) for those in the upper BMI tertile (BMI > 26.7 kg m(-2) ), as compared with the first BMI tertile (BMI < 23.5 kg m(-2) , blood group O, and no FV Leiden) (reference group). The addition of FV Leiden and blood group non-O to the model increased the risk in all BMI tertiles; the odds ratios were 3.8 (95% CI 3.2-4.6) in the third BMI tertile of individuals with blood group non-O, and 5.4 (95% CI 3.5-8.5) in the third BMI tertile of individuals with FV Leiden. When both FV Leiden and blood group non-O were present, the odds ratios were 9.1 (95% CI 5.9-14.0) in the first BMI tertile, 9.4 (95% CI 6.6-13.5) in the second BMI tertile, and 12.5 (95% CI 8.9-17.6) in the third BMI tertile. Conclusion Individuals with a high BMI, blood group non-O and/or FV Leiden have a high VT risk. The high VT risks in some subgroups may justify targeted screening and thromboprophylaxis decisions in these patients.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  body mass index; epidemiology; interaction; risk factors; thrombophilia; venous thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27214710     DOI: 10.1111/jth.13371

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner.

Authors:  Kristina Sundquist; Abrar Ahmad; Peter J Svensson; Bengt Zöller; Jan Sundquist; Ashfaque A Memon
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

Review 2.  Oestrogen and anti-androgen therapy for transgender women.

Authors:  Vin Tangpricha; Martin den Heijer
Journal:  Lancet Diabetes Endocrinol       Date:  2016-12-02       Impact factor: 32.069

3.  Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk.

Authors:  Fernanda A Orsi; Willem M Lijfering; Arnoud Van der Laarse; L Renee Ruhaak; Frits R Rosendaal; Suzanne C Cannegieter; Christa Cobbaert
Journal:  Clin Epidemiol       Date:  2019-07-22       Impact factor: 4.790

4.  Clinical factors associated with massive pulmonary embolism and PE-related adverse clinical events.

Authors:  Praveen Hariharan; Nicholas Giordano; Alona Muzikansky; Christopher Kabrhel
Journal:  Int J Cardiol       Date:  2021-01-31       Impact factor: 4.164

5.  Association between cardiovascular risk factors and venous thromboembolism in the elderly.

Authors:  Huijie Wang; Frits R Rosendaal; Mary Cushman; Astrid van Hylckama Vlieg
Journal:  Res Pract Thromb Haemost       Date:  2022-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.